Pharmacogenetics of genes across the doxorubicin pathway

Bibliography

• Dobbs NA, Twelves CJ, Gillies H, Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 1995;36(10):473-6
   PubMedGoogle Scholar
• Twelves CJ, Dobbs NA, Gillies HC, Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests. Cancer Chemother Pharmacol 1998;42(3):229-34
   PubMed Web of Science ®Google Scholar
• Mao Y, Yu C, Hsieh TS, Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 1999;38(33):10793-800
   PubMed Web of Science ®Google Scholar
• Ueda K, Cardarelli C, Gottesman MM, Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84(9):3004-8
   PubMed Web of Science ®Google Scholar
• Ueda K, Okamura N, Hirai M, Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992;267(34):24248-52
   PubMed Web of Science ®Google Scholar
• Watchko JF, Daood MJ, Hansen TWR. Brain bilirubin content is increased in P-glycoprotein-deficient transgenic null mutant mice. Pediatr Res 1998;44(5):763-6
   PubMed Web of Science ®Google Scholar
• Fairchild CR, Ivy SP, Kao-Shan C-S, Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant Human Breast cancer cells. Cancer Res 1987;47(19):5141-8
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SPC. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204(3):216-37
   PubMed Web of Science ®Google Scholar
• Chan LMS, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004;21(1):25-51
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Mol C, P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97(11):2517-24
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Mayer U, Wagenaar E, Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997;94(8):4028-33
   PubMed Web of Science ®Google Scholar
• Roulet A, Puel O, Gesta S, MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 2003;460(2-3):85-91
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455(1):152-62
   PubMed Web of Science ®Google Scholar
• Kartner N, Riordan JR, Ling V. Cell-surface P-glycoprotein associated with multidrug resistance in mammalian-cell lines. Science 1983;221(4617):1285-8
   PubMed Web of Science ®Google Scholar
• van Asperen J, van Tellingen O, Tijssen F, Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 1999;79(1):108-13
   PubMed Web of Science ®Google Scholar
• Ozols RF, Cunnion RE, Klecker RW, Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987;5(4):641-7
   PubMed Web of Science ®Google Scholar
• Erlichman C, Moore M, Thiessen JJ, Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993;53(20):4837-42
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Lum BL, Fisher GA, Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994;12(4):835-42
   PubMed Web of Science ®Google Scholar
• List AF, Kopecky KJ, Willman CL, Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98(12):3212-20
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Durie BGM, Lokhorst HM, Modulation of multidrug-resistant multiple-myeloma by cyclosporine. Lancet 1992;340(8814):255-9
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Suciu S, Weijermans P, Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001;115(4):895-902
   PubMed Web of Science ®Google Scholar
• van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 2001;97(11):3605-11
   PubMed Web of Science ®Google Scholar
• Illmer T, Schuler US, Thiede C, MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62(17):4955-62
   PubMed Web of Science ®Google Scholar
• Buda G, Maggini V, Galimberti S, MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol 2007;137(5):454-6
   PubMed Web of Science ®Google Scholar
• Maggini V, Buda G, Martino A, MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics 2008;18(5):383-9
   PubMed Web of Science ®Google Scholar
• Bray J, Sludden J, Griffin MJ, Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010;102(6):1003-9
   PubMed Web of Science ®Google Scholar
• Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003;65(11):1843-52
   PubMed Web of Science ®Google Scholar
• Jeong H, Herskowitz I, Kroetz DL, Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet 2007;3:367-76
   Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Kim I-W, A “Silent” Polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315(5811):525-8
   PubMed Web of Science ®Google Scholar
• Gow JM, Hodges LM, Chinn LW, Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther 2008;325(2):435-42
   PubMed Web of Science ®Google Scholar
• Tang K, Ngoi SM, Gwee PC, Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002;12(6):437-50
   PubMedGoogle Scholar
• Allabi AC, Horsmans Y, Issaoui B, Single nucleotide polymorphisms of <i>ABCB1</i> (<i>MDR1</i>) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol 2005;61(2):97-102
   PubMed Web of Science ®Google Scholar
• Lal S, Wong ZW, Sandanaraj E, Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008;99(4):816-23
   PubMed Web of Science ®Google Scholar
• Sakurai A, Onishi Y, Hirano H, Quantitative structure–activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry 2007;46(26):7678-93
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 2002;62(1):1-6
   PubMed Web of Science ®Google Scholar
• Kroetz DL, Pauli-Magnus C, Hodges LM, Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13(8):481-94
   PubMedGoogle Scholar
• Hoffmeyer S, Burk O, von Richter O, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97(7):3473-8
   PubMed Web of Science ®Google Scholar
• Tanabe M, Ieiri I, Nagata N, Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297(3):1137-43
   PubMed Web of Science ®Google Scholar
• Buda G, Ricci D, Huang CC, Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2010;89(11):1133-40
   PubMed Web of Science ®Google Scholar
• Nordgard SH, Ritchie MD, Jensrud SD, ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenet Genomics 2007;17(2):127-36
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Schneider E, Dixon KH, Reduced intracellular drug accumulation in the absence of P-glycoprotein (MDR1) overexpression in mitoxantrone-resistant human MCF-7 breast-cancer cells. Cancer Res 1992;52(22):6175-81
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang WD, Abruzzo LV, A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95(26):15665-70
   PubMed Web of Science ®Google Scholar
• Allikmets R, Schriml LM, Hutchinson A, A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58(23):5337-9
   PubMed Web of Science ®Google Scholar
• Miyake K, Mickley L, Litman T, Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999;59(1):8-13
   PubMed Web of Science ®Google Scholar
• Honjo Y, Hrycyna CA, Yan Q-W, Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001;61(18):6635-9
   PubMed Web of Science ®Google Scholar
• Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 2004;109(2):238-46
   PubMed Web of Science ®Google Scholar
• Frank NY, Margaryan A, Huang Y, ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65(10):4320-33
   PubMed Web of Science ®Google Scholar
• Cole SPC, Bhardwaj G, Gerlach JH, Overexpression of a transporter gene in a multidrug-resistant human lung cancer Science 1992;258(5088):1650-4
   Google Scholar
• Cui YH, Konig J, Buchholz U, Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55(5):929-37
   PubMed Web of Science ®Google Scholar
• Yoshida M, Suzuki T, Komiya T, Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to Adriamycin. Int J Cancer 2001;94(3):432-7
   PubMed Web of Science ®Google Scholar
• Goodell MA, Brose K, Paradis G, Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183(4):1797-806
   PubMed Web of Science ®Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG, A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004;101(39):14228-33
   PubMed Web of Science ®Google Scholar
• Mogi M, Yang J, Lambert JF, Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 2003;278(40):39068-75
   PubMed Web of Science ®Google Scholar
• Okabe M, Unno M, Harigae H, Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 2005;333(3):754-62
   PubMed Web of Science ®Google Scholar
• Lal S, Wong ZW, Jada SR, Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 2007;8(6):567-75
   PubMed Web of Science ®Google Scholar
• Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 2007;23(1):15-25
   PubMed Web of Science ®Google Scholar
• Mross K, Maessen P, Vandervijgh WJF, Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 1988;6(3):517-26
   PubMed Web of Science ®Google Scholar
• Olson RD, Mushlin PS, Brenner DE, Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 1988;85(10):3585-9
   PubMed Web of Science ®Google Scholar
• Olson LE, Bedja D, Alvey SJ, Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 2003;63(20):6602-6
   PubMed Web of Science ®Google Scholar
• Kassner N, Huse K, Martin HJ, Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 2008;36(10):2113-20
   PubMed Web of Science ®Google Scholar
• Bains OS, Karkling MJ, Lubieniecka JM, Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther 2010;332(3):755-63
   PubMed Web of Science ®Google Scholar
• Novotna R, Wsol V, Xiong G, Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett 2008;181(1):1-6
   PubMed Web of Science ®Google Scholar
• Bains OS, Grigliatti TA, Reid RE, Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther 2010;335(3):533-45
   PubMed Web of Science ®Google Scholar
• Bains OS, Karkling MJ, Grigliatti TA, Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos 2009;37(5):1107-14
   PubMed Web of Science ®Google Scholar
• Gonzalez-Covarrubias V, Zhang J, Kalabus JL, Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metab Dispos 2009;37(2):400-7
   PubMed Web of Science ®Google Scholar
• Fan L, Goh BC, Wong CI, Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 2008;18(7):621-31
   PubMed Web of Science ®Google Scholar
• Lal S, Sandanaraj E, Wong ZW, CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008;99(10):2045-54
   PubMed Web of Science ®Google Scholar
• Choi JY, Barlow WE, Albain KS, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res 2009;15(16):5258-66
   PubMed Web of Science ®Google Scholar
• Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H : quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008;112(12):2789-95
   PubMed Web of Science ®Google Scholar
• Tewey KM, Rowe TC, Yang L, Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226(4673):466-8
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 1999;57(7):727-41
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Shehata M, Moseley P, Topo2 alpha protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. Br J Cancer 2010;103(12):1794-800
   PubMed Web of Science ®Google Scholar
• Durbecq V, Paesmans M, Cardoso F, Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 2004;3(10):1207-14
   PubMed Web of Science ®Google Scholar
• Gennari A, Sormani MP, Pronzato P, HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008;100(1):14-20
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pauletti G, Untch M, Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat 2010;120(2):481-9
   PubMed Web of Science ®Google Scholar
• Danks MK, Yalowich JC, Beck WT. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 1987;47(5):1297-301
   PubMed Web of Science ®Google Scholar
• Akimitsu N, Adachi N, Hirai H, Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIalpha. Genes Cells 2003;8(4):393-402
   PubMed Web of Science ®Google Scholar
• Yen HC, Oberley TD, Vichitbandha S, The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1996;98(5):1253-60
   PubMed Web of Science ®Google Scholar
• Bachur NR, Gordon SL, Gee MV. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 1977;13(5):901-10
   PubMed Web of Science ®Google Scholar
• Bachur NR, Gordon SL, Gee MV, NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 1979;76(2):954-7
   PubMed Web of Science ®Google Scholar
• Sinha BK, Katki AG, Batist G, Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry 1987;26(13):3776-81
   PubMed Web of Science ®Google Scholar
• Doroshow JH. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun 1986;135(1):330-5
   PubMed Web of Science ®Google Scholar
• Kang YJ, Chen Y, Epstein PN. Suppression of cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 1996;271(21):12610-16
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Rajesh M, Batkai S, Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 2009;296(5):H1466-83
   PubMed Web of Science ®Google Scholar
• Deng SW, Kruger A, Kleschyov AL, Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med 2007;42(4):466-73
   PubMed Web of Science ®Google Scholar
• Vasquez-Vivar J, Martasek P, Hogg N, Endothelial nitric oxide synthase-dependent superoxide generation from Adriamycin. Biochemistry 1997;36(38):11293-7
   PubMed Web of Science ®Google Scholar
• Yee SB, Pritsos CA. Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase. Arch Biochem Biophys 1997;347(2):235-41
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112(24):3754-62
   PubMed Web of Science ®Google Scholar
• Rossi D, Rasi S, Franceschetti S, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009;23(6):1118-26
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Schirmer MA, Tzvetkov MV, A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-hodgkin lymphoma. Cancer Res 2010;70(6):2328-38
   PubMed Web of Science ®Google Scholar
• Glynn SA, Boersma BJ, Howe TM, A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clin Cancer Res 2009;15(12):4165-73
   PubMed Web of Science ®Google Scholar
• Akman SA, Forrest G, Chu FF, Antioxidant and xenobiotic-metabolizing enzyme gene-expression in doxorubicin-resistant MCF-7 breast-cancer cells. Cancer Res 1990;50(5):1397-402
   PubMed Web of Science ®Google Scholar
• Fagerholm R, Hofstetter B, Tommiska J, NAD(P)H : quinone oxidoreductase 1 NQO1(star)2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008;40(7):844-53
   PubMed Web of Science ®Google Scholar
• Powis G, Gasdaska PY, Gallegos A, Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug-sensitivity - A questionable role for the enzyme as a target for bioreductively activated anticancer drugs. Anticancer Res 1995;15(4):1141-5
   PubMed Web of Science ®Google Scholar
• Barragan E, Collado M, Cervera J, The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk Res 2007;31(7):947-53
   PubMed Web of Science ®Google Scholar
• Buda G, Maggini V, Galimberti S, NQO1*2 polymorphism and response to treatment in patients with multiple myeloma. Leuk Res 2007;31(8):1029-30
   PubMed Web of Science ®Google Scholar